[Cholesterol-lowering drugs in the elderly. When to initiate, maintain or discontinue therapy?]

Area of Science:

• Geriatrics
• Cardiology
• Pharmacology

Background:

• Cardiovascular disease (CVD) remains a significant health concern in the elderly population.
• Cholesterol management is a key strategy for CVD risk reduction, even in older individuals.
• Significant variability exists in CVD risk among elderly individuals, necessitating personalized approaches.

Purpose of the Study:

• To outline a framework for prescribing cholesterol-lowering drugs in the elderly.
• To emphasize the importance of individualized risk assessment in geriatric CVD prevention.
• To guide clinical decision-making regarding the initiation, continuation, or cessation of lipid-lowering therapy in older adults.

Main Methods:

• Utilizing age-adjusted, individualized cardiovascular risk scores that incorporate competing risks.
• Evaluating patient-specific factors including life expectancy, frailty, and presence of existing vascular disease.
• Considering comorbidities such as diabetes mellitus and severe hypertension as indicators of high cardiovascular morbidity risk.

Main Results:

• Cholesterol-lowering drugs are indicated for energetic elderly individuals without vascular disease only if they have a high risk of cardiovascular morbidity.
• Cholesterol-lowering drugs should not be prescribed to frail elderly individuals without vascular disease.
• Lipid-lowering therapy should be initiated or continued in elderly patients with established vascular disease, with cessation advised for severe side effects or limited life expectancy (1-2 years).

Conclusions:

• Clinical decisions regarding cholesterol-lowering drug use in the elderly must balance potential benefits against competing risks and individual patient characteristics.
• A nuanced, individualized approach is crucial for optimizing CVD prevention strategies in older adults.
• Frailty and short life expectancy are critical factors that may contraindicate or warrant discontinuation of lipid-lowering therapy in the absence of vascular disease.